PYC Therapuetics (ASX:PYC) - CEO, Rohan Hockings
CEO, Rohan Hockings
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Drugmaker PYC Therapeutics (PYC) has successfully tapped institutions for $35.2 million in the first part of a major capital raising plan
  • The company has raised $35.2 million through an institutional share placement and one-for-ten entitlement offer
  • Now, a retail segment of the entitlement offer is set to open on Monday, October 26, to raise another $19.6 million
  • All new shares under both parts of the offer are priced at 17 cents each, which is an 8.1 per cent discount to the company’s last closing price
  • The new cash will be used to develop lead PYC drugs and add 3 new people to the company’s executive team
  • Shares in PYC came out of a trading halt today and retreated just over 5 per cent to 18 cents each

PYC Therapeutics (PYC) has successfully tapped institutions for $35.2 million in the first part of a major capital raising plan.

The company revealed earlier this week a plan to raise $55 million through an entitlement offer and a share placement.

Under the plan, $5 million would be raised by placing around 29.4 million new shares to institutional investors. Institutions would also have first dibs in a $50 million 1-for-10 entitlement offer.

All new shares were priced at 17 cents a pop — a discount of around 8.1 per cent to the company last closing price before the announcement was made.

Today, the company said it successfully completed both institutional parts of the raise — pulling in the full $5 million through the placement and another $30.2 million through the institutional entitlement offer.

Importantly, PYC’s biggest shareholder, Australian Land, took up as much as it could under the pro-rata offer with a $15 million investment.

PYC CEO Dr Rohan Hockings said this is a very strong start to the financing plan.

“We are now funded through the clinical readouts that represent the next horizon for our precision medicine technology and its path to market,” Rohan said.

Now, the retail segment of the entitlement offer will open, with the company planning to raise $19.6 million from mum and dad investors under the same terms as the institutional offer. The retail offer opens on Monday, October 26.

PYC will use the new cash to develop its lead drug program, VP-001, through to market, as well as develop 2 new ocular drugs dubbed PYC-001 and VP-002.

On top of this, PYC said it is playing with the idea of a NASDAQ listing by 2022 as well as adding three new people to its executive team.

PYC shares came out of a trading halt today and retreated slightly towards the capital raise price. Shares closed 5.41 per cent lower at 18 cents each.

PYC by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…